UBS O'Connor’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-26,899
Closed -$194K 333
2024
Q4
$194K Buy
26,899
+4,851
+22% +$37.1K ﹤0.01% 334
2024
Q3
$135K Sell
22,048
-17,952
-45% -$122K ﹤0.01% 401
2024
Q2
$266K Sell
40,000
-16,795
-30% -$124K 0.01% 404
2024
Q1
$578K Buy
56,795
+22,497
+66% +$229K 0.02% 322
2023
Q4
$386K Buy
+34,298
New +$143K 0.01% 376

Other funds holding ALT

UBS O'Connor's ALT Position: Q1 2025 in Review

UBS O'Connor sold out of Altimmune (ALT) in Q1 2025, closing a stake of 26,899 shares — an estimated $194K sold.

UBS O'Connor first reported a position in ALT in Q4 2023 and held it in 5 quarters. The position peaked at $578K in Q1 2024. 176 funds tracked by Wall St. Rank hold ALT as of Q1 2025.

  • UBS O'Connor reported no remaining Altimmune position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 26,899 Altimmune shares in Q1 2025, an estimated $194K.
  • UBS O'Connor first reported a position in Altimmune in Q4 2023 and held it in 5 quarters.
  • UBS O'Connor's Altimmune position peaked at $578K in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Altimmune as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.